Phase 2 study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) therapy for refractory/relapsed malignant lymphoma.
Phase 2
- Conditions
- malignant lymphoma
- Registration Number
- JPRN-UMIN000011682
- Lead Sponsor
- TOHOKU HEMATOLOGY FORUM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1 Neutrophils <1000/mm3 2 Platelet <75,000/mm3 3 Cre >1.5mg/dL 4 AST or ALT > 5xULN, T.Bil >2.0mg/dL 5 Angina pectoris, myocardial infarction, treatment required arrhythmia 6 Interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema 7 Patients with CNS invasion of lymphoma cells 8 Radiation therapy for thorax 9 Severe bacterial infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method